Aleksandra Stańczak at the Cancer Molecular Biology in Clinical Practice

Aleksandra Stańczak, PhD, Leader of the Oncology Research Team took part in the 7th edition of the conference: “Cancer Molecular Biology in Clinical Practice”, which was held at the end of November 2017 in Warsaw. At the: conference Ms Stańczak presented the most important assumptions of the project:  CELONKO – Development of modern biomarkers andRead more »

Conclusion of the decentralised marketing authorisation procedure for Salmex in Scandinavian countries

The procedure included: Sweden, Finland, Norway, Denmark and Iceland. The Company’s business partner in the scope of obtaining marketing authorisation and product distribution in the markets covered by the DCP is Glenmark. The countries covered by the Scandinavian procedure have issued positive decisions on acceptance of the submitted marketing authorisation dossier. Bogdan Manowski, Director forRead more »

Celon Pharma S.A. receives a positive recommendation of the National Centre for Research and Development o co-funding of the development of the drug candidate for treatment of type 2 diabetes

Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: We are very pleased about it. Our application was received a very good grade in the expert assessment and was placed high on the ranking. This project in the area of metabolic diseases is currently very important to us. First we are facing toxicological tests,Read more »

Announcement of the Management Board of Celon Pharma S.A.

Ladies and Gentlemen, In connection with the information provided yesterday by Selvita S.A. on withholding the clinical programme for SEL24, the Management Board of Celon Pharma S.A. informs that such situations occur naturally in the process of creating innovative medicinal products, as demonstrated by numerous examples of clinical projects carried out in American or EuropeanRead more »